快速起作用的NMDA和GABAergic调节器在情绪障碍中:从突触机制到临床实践
1Department of Medicine and Surgery, Kore University of Enna, Enna, Italy.
概括
两种新型快速起作用的抑郁症治疗方法,NMDA受体调节剂和神经类固醇GABA-A调节剂,为恢复大脑电路功能和改善情绪障碍治疗提供了互补的方法.
科学领域:
- 神经科学和精神病学 在
- 情绪障碍的药理学 情绪障碍的药理学
背景情况:
- 抑郁症越来越多地被理解为突触可塑性和皮质膜回路中的兴奋抑制不平衡的障碍.
- 现有的治疗方法往往起作用缓慢,突出显示需要快速起作用的治疗方案.
研究的目的:
- 审查两类快速起作用抗抑郁药的疗效和安全性:NMDA受体调节剂和神经活性类固醇GABA-A阳性全调节剂.
- 讨论它们在恢复电路功能和治疗情绪障碍,包括耐治疗和双极性抑郁症中的互补作用.
主要方法:
- 审查了胺,胺,布雷克萨诺龙和祖拉诺龙的临床疗效和安全数据.
- 关注与安慰剂和活性比较剂的比较有效性,以及特定患者群体 (例如,TRD,产后抑郁症).
主要成果:
- NMDA受体调节剂 (胺,胺) 在耐治疗抑郁症中表现出优越性,并迅速减少自杀念头.
- 神经类固醇GABA-A调节剂在产后抑郁症中有效,并且在主要抑郁症中表现出初步疗效,通常与抗抑郁药一起使用.
- 副作用包括NMDA调节器的解离和血液动力学变化,以及GABA-A调节器的镇静.
结论:
- NMDA受体调节器和神经类固醇GABA-A调节器代表了情绪障碍治疗的重大进展.
- 这些疗法促进了转向机制驱动的护理,提供快速缓解和改善患者的结果.
- 仔细的患者选择和监测对于优化治疗效益和管理潜在风险至关重要.
更多相关视频
04:48A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate
Published on: July 10, 2018
9.7K
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
14.2K
相关概念视频
01:14Antiepileptic Drugs: Glutamate Antagonists
888
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
888
01:23Antidepressant Drugs: MAOIs and Other Agents
806
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
806
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
01:24Mania and Antimanic Drugs: Overview
545
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
545
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
3.8K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
3.8K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
814
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
814